These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26239948)

  • 1. Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data.
    Rodby RA; Umanath K; Niecestro R; Bond TC; Sika M; Lewis J; Dwyer JP;
    Drugs R D; 2015 Sep; 15(3):271-9. PubMed ID: 26239948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.
    Umanath K; Jalal DI; Greco BA; Umeukeje EM; Reisin E; Manley J; Zeig S; Negoi DG; Hiremath AN; Blumenthal SS; Sika M; Niecestro R; Koury MJ; Ma KN; Greene T; Lewis JB; Dwyer JP;
    J Am Soc Nephrol; 2015 Oct; 26(10):2578-87. PubMed ID: 25736045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model.
    Brunelli SM; Sibbel SP; Van Wyck D; Sharma A; Hsieh A; Chertow GM
    Drugs R D; 2017 Mar; 17(1):159-166. PubMed ID: 28078600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.
    Mutell R; Rubin JL; Bond TC; Mayne T
    Int J Nephrol Renovasc Dis; 2013; 6():79-87. PubMed ID: 23662073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Trial of the Impact of Ferric Citrate on Erythropoietin and Intravenous Iron Use in Patients Receiving Dialysis.
    Block GA; Mizani MR; Broumand V; Newby FD; Erinle A; Arias C; Block M; Brillhart S; Leppink A; Danese M; Dittrich M
    Am J Nephrol; 2024; 55(5):520-528. PubMed ID: 38972306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs.
    Rodby R; Umanath K; Niecestro R; Jackson JH; Sika M; Lewis JB; Dwyer JP;
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):545-50. PubMed ID: 25495878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
    Keith MS; Wilson RJ; Preston P; Copley JB
    Clin Ther; 2014 Sep; 36(9):1276-86. PubMed ID: 25069799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric citrate controls phosphorus and delivers iron in patients on dialysis.
    Lewis JB; Sika M; Koury MJ; Chuang P; Schulman G; Smith MT; Whittier FC; Linfert DR; Galphin CM; Athreya BP; Nossuli AK; Chang IJ; Blumenthal SS; Manley J; Zeig S; Kant KS; Olivero JJ; Greene T; Dwyer JP;
    J Am Soc Nephrol; 2015 Feb; 26(2):493-503. PubMed ID: 25060056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferric citrate hydrate is associated with a reduced cost of drugs and a smaller change in red blood cell distribution width.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    Sci Rep; 2022 Feb; 12(1):2406. PubMed ID: 35165297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial of ferric citrate hydrate on anaemia management in haemodialysis patients with hyperphosphataemia: ASTRIO study.
    Yokoyama K; Fukagawa M; Akiba T; Nakayama M; Ito K; Hanaki K; Wolf M; Hirakata H
    Sci Rep; 2019 Jun; 9(1):8877. PubMed ID: 31222044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
.
    Umanath K; Greco B; Jalal DI; McFadden M; Sika M; Koury MJ; Niecestro R; Hunsicker LG; Greene T; Lewis JB; Dwyer JP
    Clin Nephrol; 2017 Mar; 87 (2017)(3):124-133. PubMed ID: 28128726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferric Citrate in Patients With Chronic Kidney Disease.
    Block GA
    Semin Nephrol; 2016 Mar; 36(2):130-5. PubMed ID: 27236135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
    St Peter WL; Wazny LD; Weinhandl ED
    Am J Kidney Dis; 2018 Feb; 71(2):246-253. PubMed ID: 29195858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness of Iron and Erythropoiesis-Stimulating Agent Dosing on Health-Related Quality of Life in Patients Receiving Hemodialysis.
    Freburger JK; Ellis AR; Wang L; Butler AM; Kshirsagar AV; Winkelmayer WC; Brookhart MA
    Am J Kidney Dis; 2016 Feb; 67(2):271-82. PubMed ID: 26508682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of costs for anemia-management drugs associated with the use of ferric citrate.
    Thomas A; Peterson LE
    Int J Nephrol Renovasc Dis; 2014; 7():191-201. PubMed ID: 24899820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010).
    Winkelmayer WC; Mitani AA; Goldstein BA; Brookhart MA; Chertow GM
    JAMA Intern Med; 2014 May; 174(5):699-707. PubMed ID: 24589911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective.
    Luporsi E; Mahi L; Morre C; Wernli J; de Pouvourville G; Bugat R
    J Med Econ; 2012; 15(2):225-32. PubMed ID: 22077267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic impact of improving phosphate binder therapy adherence and attainment of guideline phosphorus goals in hemodialysis patients: a Medicare cost-offset model.
    Ramakrishnan K; Braunhofer P; Newsome B; Lubeck D; Wang S; Deuson J; Claxton AJ
    Adv Ther; 2014 Dec; 31(12):1272-86. PubMed ID: 25479935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.